Not applicableStudy completedNCT05754047What this trial is testingTumor Characteristics and Survival Rate of HER2-Low Breast Cancer PatientsWho this might be right forHER2 Low Breast Carcinoma Mahdis Bayat 3,582
Testing effectiveness (Phase 2)Looking for participantsNCT06224673What this trial is testingARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast CancerWho this might be right forHER2 Low Breast CarcinomaTriple Negative Breast CancerHormone-receptor-positive Breast Cancer+1 more Laura Huppert, MD, BA 36
Early research (Phase 1)Looking for participantsNCT07137416What this trial is testingTesting the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast CancerWho this might be right forAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Invasive Breast Carcinoma+13 more National Cancer Institute (NCI) 36
Large-scale testing (Phase 3)Active Not RecruitingNCT06144944What this trial is testingNeoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast CancerWho this might be right forBreast Cancer InvasiveHormone-receptor-positive Breast CancerHER2 Low Breast Carcinoma+1 more Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 160
Large-scale testing (Phase 3)Looking for participantsNCT07762885What this trial is testingOmission of Adjuvant Radiotherapy in Low- and Intermediate-Risk Ductal Carcinoma In Situ After Breast-Conserving SurgeryWho this might be right forDuctal Carcinoma In Situ, DCIS Fudan University 636
Not applicableLooking for participantsNCT07613151What this trial is testingNegative/Low Hormone Receptor And/or HER2 POsitive Lobular Invasive Breast Carcinoma - A Real-World International Cohort StudyWho this might be right forLobular Breast Carcinoma Istituto Oncologico Veneto IRCCS 250
Large-scale testing (Phase 3)Temporarily pausedNCT06671912What this trial is testingTesting Low Dose Tamoxifen for Invasive Breast Cancer, LoTam TrialWho this might be right forAnatomic Stage 0 Breast Cancer AJCC v8Anatomic Stage 1 Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8+4 more Alliance for Clinical Trials in Oncology 1,556
Early research (Phase 1)WithdrawnNCT04602117What this trial is testingISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic CancerWho this might be right forHER2-positive Breast CancerHER2 LowSYD-985+24 more QuantumLeap Healthcare Collaborative
Testing effectiveness (Phase 2)Looking for participantsNCT05911958What this trial is testingSHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast CancerWho this might be right forHER2 Low Breast Carcinoma Henan Cancer Hospital 66
Testing effectiveness (Phase 2)Looking for participantsNCT05795101What this trial is testingTRUDI: TDXD+Durva in HER2+/Low IBCWho this might be right forInvasive Breast CancerInflammatory Breast Cancer Stage IIIHER2-positive Breast Cancer+2 more Filipa Lynce, MD 63
Testing effectiveness (Phase 2)Looking for participantsNCT05868226What this trial is testingPRE-ISPY Phase I/II Oncology Platform ProgramWho this might be right forHER2-positive Breast CancerMetastatic CancerMetastatic Breast Cancer+29 more QuantumLeap Healthcare Collaborative 280
Testing effectiveness (Phase 2)Active Not RecruitingNCT06157892What this trial is testingDisitamab Vedotin With Other Anticancer Drugs in Solid TumorsWho this might be right forBreast NeoplasmsGastroesophageal Junction AdenocarcinomaHER2 Low Breast Neoplasms+7 more Seagen, a wholly owned subsidiary of Pfizer 54
Not applicableLooking for participantsNCT06805812What this trial is testingPredicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 StudyWho this might be right forBreast AdenocarcinomaBreast Cancer Stage IVBreast Cancer, Metastatic+38 more Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 3,500
Testing effectiveness (Phase 2)Looking for participantsNCT07198724What this trial is testingERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast CancerWho this might be right forMetastatic Breast CancerHER2 Low Breast CarcinomaHER2-negative Breast Cancer+2 more Kristina A. Fanucci 65
Testing effectiveness (Phase 2)Looking for participantsNCT06330064What this trial is testingEvaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)Who this might be right forRecurrent or Metastatic Solid Tumors Daiichi Sankyo 680
Testing effectiveness (Phase 2)Looking for participantsNCT05150691What this trial is testingA Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid TumorsWho this might be right forHER2-positive Advanced Solid Tumor DualityBio Inc. 796
Testing effectiveness (Phase 2)Looking for participantsNCT06298084What this trial is testingDose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXdWho this might be right forBreast Cancer MetastaticHER2-positive Metastatic Breast CancerHER2 Low Breast Carcinoma+1 more Gustave Roussy, Cancer Campus, Grand Paris 152
Testing effectiveness (Phase 2)Looking for participantsNCT07796880What this trial is testingNeoadjuvant Culmerciclib Combined With Endocrine Therapy for Hormone Receptor-Positive， Human Epidermal Growth Factor Receptor 2-Negative Breast CancerWho this might be right forHormone Receptor-Positive Breast CancerHER2 Low Breast CarcinomaEarly-Stage Breast Cancer Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 80